In Fig. 5C, expression levels of Znf179 were used to stratify grade II glioma patients into two subgroups (low- and high-risk groups): the low-risk group with higher Znf179 expression levels exhibited longer survival rates (green line in Fig. 5D), whereas the high-risk group with lower Znf179 expression exhibited shorter survival times (red line in Fig. 5D). Here, RNF112 is linked to central nervous system cancer.